The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1436
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer), which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas), another new drug for this indication, will be reviewed in a future issue.

DRUGS FOR PAH — Current management of PAH usually includes warfarin (Coumadin, and others) and furosemide (Lasix, and generics). Oral drugs approved specifically for PAH include the phosphodiesterase 5 (PDE5) inhibitors sildenafil (Revatio, and generics) and tadalafil (Adcirca),1 bosentan, and ambrisentan (Letairis), a selective endothelin type A receptor ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Macitentan (Opsumit) for Pulmonary Arterial Hypertension
Article code: 1436b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian